Dacinostat (formerly LAQ824; NVP-LAQ824) is a novel, potent and hydroxamate-based inhibitor of histone deacetylase (HDAC) with potential anticancer activity. It inhibits HDAC with an IC50 of 32 nM; It shows potent anti-proliferative activity in vitro against various cancer cell lines such as H23 and H460 cell lines.

Tasquinimod (also known as ABR215050), a quinoline-3-carboxamide linomide analogue and an investigational drug, is a novel, and orally bioactive anti-angiogenic agent which potently inhibits HDAC4 allosterically with with potential anticancer activity.

HDAC-IN-4 (also known as CXD101, AZD9468) is a novel and potent inhibitor of histone deacetylase (HDAC) with potential anticancer and immunomodulatory activity.

Elevenostat (JB3-22) is a potent HDAC11 inhibitor (IC50=0.235 µM) with anticancer and anti-multiple myeloma (MM) activity.

Trichostatin A (also called TSA) is a novel, potent and specific inhibitor of histone deacetylase (HDAC) with potential anticancer activity.

Abexinostat (formerly PCI-24781; CRA-024781) is a novel, potent and hydroxamic acid-based pan-HDAC (histone deacetylase) inhibitor with potential anticancer activity.

Vorinostat (formerly known as suberanilohydroxamic acid, MK-0683; CCRIS-8456; HSDB 7930; SAHA; trade name: Zolinza) is a potent, orally bioavailable and non-selective pan-inhibitor of histone deacetylases (HDACs) with antitumor activity.

MC1568 is a hydroxyamide-based inhibitor of class II histone deacetylase (HDAC) such as HDAC4/5/6/7/9 (IIa) and HDAC6/10 (IIb) with potential antiviral activity.

CAY10603 is a novel, potent and selective HDAC6 (Histone deacetylase) inhibitor with potential anticancer activity and a potential to treat neurodegenerative diseases.

SKLB-23bb (HDAC6-IN-1; 23bb) is a novel, potent, orally bioavailable and selective inhibitor for histone deacetylase 6 (HDAC6) with anticancer, anti-mitotic/antitubulin and neuroprotective effects.